Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-9243.05%
operating margin TTM
-9396.64%
revenue TTM
30.79 Million
revenue per share TTM
0.65$
valuation ratios | |
|---|---|
| pe ratio | -3.33 |
| peg ratio | 0.12 |
| price to book ratio | 5.75 |
| price to sales ratio | 308.06 |
| enterprise value multiple | -3.67 |
| price fair value | 5.75 |
profitability ratios | |
|---|---|
| gross profit margin | 66.43% |
| operating profit margin | -9396.64% |
| pretax profit margin | -9241.45% |
| net profit margin | -9243.05% |
| return on assets | -73.99% |
| return on equity | -121.71% |
| return on capital employed | -82.73% |
liquidity ratios | |
|---|---|
| current ratio | 9.83 |
| quick ratio | 9.83 |
| cash ratio | 0.54 |
efficiency ratios | |
|---|---|
| days of inventory outstanding | 0.00 |
| operating cycle | 8,799.70 |
| days of payables outstanding | 12,231.04 |
| cash conversion cycle | -3,431.34 |
| receivables turnover | 0.04 |
| payables turnover | 0.03 |
| inventory turnover | 0.00 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.00 |
| debt equity ratio | 0.00 |
| long term debt to capitalization | 0.00 |
| total debt to capitalization | 0.00 |
| interest coverage | 0.00 |
| cash flow to debt ratio | -482.10 |
cash flow ratios | |
|---|---|
| free cash flow per share | -1.39 |
| cash per share | 1.48 |
| operating cash flow per share | -1.39 |
| free cash flow operating cash flow ratio | 1.00 |
| cash flow coverage ratios | -482.10 |
| short term coverage ratios | -705.00 |
| capital expenditure coverage ratio | -618.54 |
Frequently Asked Questions
When was the last time Silence Therapeutics plc (NASDAQ:SLN) reported earnings?
Silence Therapeutics plc (SLN) published its most recent earnings results on 07-05-2026.
What is Silence Therapeutics plc's current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Silence Therapeutics plc (NASDAQ:SLN)'s trailing twelve months ROE is -121.71%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Silence Therapeutics plc (SLN) currently has a ROA of -73.99%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did SLN's net profit margin stand at?
SLN reported a profit margin of -9243.05% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is SLN's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 9.83 in the most recent quarter. The quick ratio stood at 9.83, with a Debt/Eq ratio of 0.00.